Index

Note: Page numbers of article titles are in **boldface** type.

A

N-Acetylcysteine, in hepatic dysfunction management, 755
Activated partial thromboplastin time, coagulation defects and, 787–788
Activated protein C, for coagulation defects, 792–793
Acute kidney injury (AKI), RIFLE classification scheme for, 733
Acute liver failure (ALF). See also Hepatic dysfunction.
  CNS dysfunction in, 749–750
  described, 745
  in dogs and cats, causes of, 746, 747
  risk factors for, 750–751
Acute lung injury (ALI)
  critical illness and, 712
  treatment of, 712–714
Acute Physiology and Chronic Health Evaluation II scoring system, 705
Acute renal failure (ARF)
  AKI and, 733–734
  causes of, 734–736
  community-acquired, 735
  defined, 733
  early detection of, 738–739
  hospital-acquired, 735–736
  prevention of, 737–739
    risk factor awareness in, 737
    risk factor management in, 737–738
  management of, 739–742
  normotensive ischemic, 737
  pathophysiology of, 734
Acute respiratory distress syndrome (ARDS)
  critical illness and, 709
  pathophysiology of, 712
  treatment of, 712–714
S-Adenosylmethionine (SAMe), in hepatic dysfunction management, 753–755
AKI. See Acute kidney injury (AKI).
ALF. See Acute liver failure (ALF).
ALI. See Acute lung injury (ALI).
Analgesia/analgesics, for gastrointestinal dysfunction due to critical illness in small animals, 764
Antibacterials, in critical care setting, 812
Antibiotics, for gastrointestinal dysfunction due to critical illness in small animals, 763
Antiemetics, for gastrointestinal dysfunction due to critical illness in small animals, 764
Antioxidants, in hepatic dysfunction management, 753–755
Antithrombin, coagulation defects and, 789, 791–792
ARDS. See Acute respiratory distress syndrome (ARDS).
ARF. See Acute renal failure (ARF).
Arginine, for gastrointestinal dysfunction due to critical illness in small animals, 763–764
Ascites, in hepatic dysfunction, 748–749
Autonomic impairment, in sepsis and critical illness, 722–723
Azotemia
- approach to, clinical questions related to, 731
- defined, 728
- prerenal, renal, and postrenal, differentiation among, 729–731
- renal failure and, 728–731

B
Bacterial translocation, 760
Base excess, in microvascular monitoring in goal-directed therapy in critically ill animals, 826–827
Benzodiazepines, in critical care setting, 810–811
Blood pressure, in macrovascular monitoring in goal-directed therapy in critically ill animals, 819–822

C
Cardiovascular system
- critical illness effects on, 717–726
- drug disposition and therapeutic response related to, 810
- sepsis effects on, 717–726. See also Sepsis, cardiovascular dysfunction in.
Cat(s), ALF in, causes of, 746, 747
Central nervous system (CNS), dysfunction of, in ARF, 749–750
Central venous oxygen saturation, in microvascular monitoring in goal-directed therapy in critically ill animals, 825–826
Central venous pressure, in macrovascular monitoring in goal-directed therapy in critically ill animals, 818–819
Chronic kidney disease (CKD)
- defined, 732
- staging of, 732
CIRCI. See Critical illness–related corticosteroid insufficiency (CIRCI).
CKD. See Chronic kidney disease (CKD).
CNS. See Central nervous system (CNS).
Coagulation
- defects in
  - activated partial thromboplatin time and, 787–788
  - antithrombin and, 789
  - detection of, platelet function assays in, 788–789
  - diagnosis of, 786–787
  - fibrinolysis assessment in, 789
  - in critical illness, 783–803
  - microparticles and, 788
  - platelet count and, 787
  - protein C activity and, 789
  - prothrombin and, 787–788
  - treatment of, 790–795
activated protein C in, 792–793
antithrombin in, 791–792
fresh frozen plasma in, 790–791
heparin in, 793–795
platelet transfusion in, 793
vitamin K in, 795
viscoelastic coagulation monitoring of, 788
inflammation effects on, 783–784
intravascular thrombosis and, 784–785
Community-acquired acute renal failure, 735
Critical illness. See also specific types.
cardiovascular dysfunction in, 717–726. See also Sepsis, cardiovascular dysfunction in.
corticosteroid insufficiency due to, 767–782. See also Critical illness–related corticosteroid insufficiency (CIRCI).
drug metabolism alterations during, 805–815
drugs used in, 810–812. See also specific drugs.
gastrointestinal dysfunction due to, 759–766. See also Gastrointestinal dysfunction.
goal-directed therapy in, 817–833. See also Goal-directed therapy, in critically ill animals.
kidney in, 727–744. See also Kidney(s), critical illness effects on.
physiologic alterations in
drug disposition effects of, 808–810
therapeutic response effects of, 808–810
respiratory complications of, 709–716. See also Respiratory disorders, complications associated with, critical illness and.
Critical illness–related corticosteroid insufficiency (CIRCI), 767–782
clinical signs of, 774–775
diagnosis of, 775–777
incidence of, 770–774
syndrome of, described, 767–768
treatment of, 777–778

D
Diarrhea, hemorrhagic, critical illness in small animals and, 760–761
DIC. See Disseminated intravascular coagulation (DIC).
Disseminated intravascular coagulation (DIC). See also Coagulation, defects in.
coagulation defects and, 783–784
described, 783–784
treatment of, 789–790
Dog(s)
ALF in, causes of, 746, 747
cardiac performance in septic shock in, 718–719
Drug disposition, physiologic alterations in critical illness effects on, 808–810
Drug metabolism, alterations of, in critically ill animals, 805–815. See also specific drugs.

E
Early goal-directed therapy (EGDT)
adjunctive therapies for, 830–831
goals of, 830–831
in critically ill animals, 827–831
Early goal-directed therapy (EGDT) bundle, in critically ill animals, step-by-step approach, 827–830
EGDT. See Early goal-directed therapy (EGDT).
Electrolyte abnormalities, in hepatic dysfunction, 748–749
Endothelial cell damage, MODS and, 712

F
Fibrinolysis, assessment of, coagulation defects and, 789
Fluid therapy, for gastrointestinal dysfunction due to critical illness in small animals, 762
Flumazenil, in hepatic dysfunction management, 754
Fresh frozen plasma, for coagulation defects, 790–791

G
Gastrointestinal dysfunction
  bacterial translocation and, 760
critical illness in small animals and, 759–766, 809–810
diagnostic evaluation of, 761–762
drug disposition and therapeutic response related to, 809–810
hemorrhagic diarrhea, 760–761
prognosis of, 764
symptoms of, 759
treatment of
  analgesics in, 764
  antibiotics in, 763
  antiemetics in, 764
  arginine in, 763–764
  fluid therapy in, 762
  glutamine in, 763
  omega-3 fatty acid supplementation in, 763–764
  symptomatic, 762
Gastrointestinal tract, defense mechanisms of, 760
Glucocorticoid(s), reduced access to target tissues and cells during illness, 770
Glucocorticoid synthesis, decreased, during illness, 768–770
Glutamine, for gastrointestinal dysfunction due to critical illness in small animals, 763
Glutathione, in hepatic dysfunction management, 754–755
Goal-directed therapy, in critically ill animals, 817–833
  advanced monitoring in, 827–831
  early, 827–831
  macrovascular monitoring in
    blood pressure, 819–822
    central venous pressure, 818–819
    urine output, 822–823
    vs. microvascular monitoring, 817–818
  microvascular monitoring in
    base excess, 826–827
    central venous oxygen saturation, 825–826
    lactate and lactate clearance, 823–825
Heart rate, in sepsis and critical illness, 722–723
Hemorrhagic diarrhea, critical illness in small animals and, 760–761
Hemostasis
  metabolic disease and, 786
  trauma and, 785–786
Heparin, for coagulation defects, 793–795
Hepatic dysfunction, 745–758
  defined, 745–746
  diagnosis of, 751–753
  indicators of, 751–753
  manifestations of
    ascites, 748–749
    electrolyte abnormalities, 748–749
  prognosis of, 756
  risk factors for, 750–751
  sepsis and, 746–748
  treatment of, 753–755
    N-acetylcysteine in, 755
    antioxidants in, 753–755
    goals of, 753
    milk thistle in, 755
    SAMe in, 753–755
    vitamin E in, 755
Hospital-acquired acute renal failure, 735–736
  prevention of, 737–739
Hypothalamic-pituitary-adrenal (HPA) axis
  abnormal response of, during illness, 768–770
  activation of, 767
  normal regulation of, during illness, 768
Immunity, innate, toll-like receptors and, in sepsis and critical illness, 720
Inflammation, coagulation effects of, 783–784
Innate immunity, toll-like receptors and, in sepsis and critical illness, 720
Intravascular thrombosis, coagulation effects of, 784–785
Kidney(s)
  critical illness effects on, 727–744
    drug disposition and therapeutic response related to, 808–809
    normal functions of, 727–728
Kidney disease. See also Acute renal failure (ARF).
  in critically ill small animals, 727–744
    chronic disease, definition and staging of, 732
Lactate, in microvascular monitoring in goal-directed therapy in critically ill animals, 823–825
Lactate clearance, in microvascular monitoring in goal-directed therapy in critically ill animals, 823–825
Lactulose, in hepatic dysfunction management, 754
Liver
critical illness effects on, drug disposition and therapeutic response related to, 809
dysfunction of, 745–758. See also Hepatic dysfunction.

M
Mannitol, in hepatic dysfunction management, 754
Metabolic disease, hemostatic defects secondary to, 786
Metronidazole, in hepatic dysfunction management, 754
Microparticles, coagulation defects and, 788
Milk thistle, in hepatic dysfunction management, 755
MODS. See Multiple organ dysfunction syndrome (MODS).
MOF. See Multiple organ failure (MOF).
Multiple Organ Dysfunction Score, 705
Multiple organ dysfunction syndrome (MODS)
  adverse effects of, 712
  clinical scoring systems for, 705
  defined, 703
  diagnostic evaluation of, 705–706
  endothelial cell damage due to, 712
  epidemiology of, 704
  history of, 703–704
  introduction to, 703–707
  pathophysiology of, 704–705
Multiple organ failure (MOF). See also Multiple organ dysfunction syndrome (MODS).
  defined, 703
  history of, 703–704
  introduction to, 703–707
Myocardial depression, in sepsis and critical illness, 722–723
Myocardial dysfunction
  cascade of events from trigger to, 721–722
  sepsis-induced, mechanisms of, 719

N
Neomycin, in hepatic dysfunction management, 754
Normotensive ischemic acute renal failure, 737

O
Omega-3 fatty acid supplementation, for gastrointestinal dysfunction due to critical illness
  in small animals, 763–764
Opioid(s), in critical care setting, 811

P
Pharmacokinetics, described, 805–808
Platelet count, coagulation defects and, 787
Platelet function assays, in coagulation defects detection, 788–789
Platelet transfusion, for coagulation defects, 793
Propofol, in critical care setting, 811–812
Protein C, activated, for coagulation defects, 792–793
Protein C activity, coagulation defects and, 789
Prothrombin, coagulation defects and, 787–788

R

Renal failure
  acute. See Acute renal failure (ARF).
  azotemia and, 728–731
  uremia and, 728–731

Renal function
  normal, 727–728
  worsening, signs of, 728

Respiratory disorders, complications associated with, critical illness and, 709–716
  ALI, 712
  ARDS, 709
  prevalence of, 709
  SIRS, 709–712

S
SAMe. See S-Adenosylmethionine (SAMe).
Sepsis
  ACCP/SCCM consensus conference definitions of, 710
  autonomic impairment associated with, 722–723
  cardiovascular dysfunction in, 717–726
    cascade of events from trigger to myocardial dysfunction, 721–722
    heart rate–related, 722–723
    myocardial depression, 722–723
    myocardial dysfunction, mechanisms of, 719
    septic shock, 717–719
    therapeutic potentials, 723–724
    toll-like receptors and innate immunity, 720
  critical illness and, 709–712
  hepatic manifestations of, 746–748
  stages of, 711
Septic shock, cardiac performance in, 717–719
  in dogs, 718–719
  in humans, 717–718
Sequential Organ Failure Assessment, 705
Shock, septic. See Septic shock.
SIRS. See Systemic inflammatory response syndrome (SIRS).
Sonoclot, 788
Systemic inflammatory response syndrome (SIRS), to infection, 710

T
TEG. See Thromboelastography (TEG).
Therapeutic response, physiologic alterations in critical illness effects on, 808–810
Thrombocytopenia, causes of, 787
Thromboelastography (TEG), 788
Thrombosis(es), intravascular, coagulation effects of, 784–785
Toll-like receptors, innate immunity and, in sepsis and critical illness, 720
Transfusion, platelet, for coagulation defects, 793
Translocation, bacterial, 760
Trauma, hemostasis and, 785–786

U
Uremia
  defined, 728
  renal failure and, 728–731
Urine output, in macrovascular monitoring in goal-directed therapy in critically ill animals, 822–823

V
Viscoelastic coagulation monitoring, 788
Vitamin E, for hepatic dysfunction, 755
Vitamin K, for coagulation defects, 795